TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compare...
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM....
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy....
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compar...
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on my...
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy....
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multipl...
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
This is a Phase IIA, randomized, double blind, placebo controlled, multicenter study designed to assess the safety, feasibility, and efficacy of umbilical cord derived mesenchymal stromal cells (UC MS...
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)....
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyop...
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM...
Top Cities for Cardiomyopathy Clinical Trials
Cardiomyopathy clinical trials are recruiting across 50 cities. Here are the cities with the most active studies:
About Cardiomyopathy
Cardiomyopathy refers to diseases of the heart muscle that make it harder for the heart to pump blood. Types include dilated, hypertrophic, and restrictive cardiomyopathy. Treatment depends on the type and may include medications, devices, or heart transplant.
Clinical trials are advancing new treatments for cardiomyopathy. Currently, 11 studies are recruiting a combined 3,616 participants across the United States. Research is being conducted by 10 organizations including Alnylam Pharmaceuticals, Intellia Therapeutics, Cytokinetics and 7 others.
2026 Cardiomyopathy Research Landscape
As of March 2026, the cardiomyopathy clinical trial landscape includes 11 actively recruiting studies across 50 cities in the United States. These studies are collectively seeking 3,616 participants, with an average enrollment target of 329 per study.
Research is being led by 10 different organizations, including Alnylam Pharmaceuticals, Intellia Therapeutics, Cytokinetics, Lexicon Pharmaceuticals, Dennis M. McNamara, MD, MS, and 5 others.
Geographically, cardiomyopathy trials are most concentrated in Los Angeles, California (8 trials); Boston, Massachusetts (5 trials); Washington D.C., District of Columbia (4 trials); San Francisco, California (4 trials); Stanford, California (4 trials) and 7 other cities.
Featured Cardiomyopathy Studies
Highlighted recruiting studies for cardiomyopathy, selected by enrollment size and research scope.
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Frequently Asked Questions About Cardiomyopathy Clinical Trials
Are there cardiomyopathy clinical trials near me?
Yes, there are 11 cardiomyopathy clinical trials currently recruiting across 50+ cities in the United States, including Los Angeles, California; Boston, Massachusetts; Washington D.C., District of Columbia. Browse the studies above to find one at a location convenient for you.
How do I join a cardiomyopathy clinical trial?
To join a cardiomyopathy clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are cardiomyopathy clinical trials free?
Yes, participation in cardiomyopathy clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of cardiomyopathy treatments are being studied?
Current cardiomyopathy clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 10 research organizations.
Is it safe to participate in cardiomyopathy clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 2, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 2, 2026 · Data from ClinicalTrials.gov